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Substrate reduction
therapy for Krabbe disease
and metachromatic
leukodystrophy using a novel
ceramide galactosyltransferase
inhibitor
Michael C. Babcock1,5, Christina R. Mikulka2,5, Bing Wang1, Sanjay Chandriani1,
Sundeep Chandra1, Yue Xu1, Katherine Webster1, Ying Feng1, Hemanth R. Nelvagal4,
Alex Giaramita1, Bryan K. Yip1, Melanie Lo1, Xuntian Jiang2, Qi Chao1, Josh C. Woloszynek1,
Yuqiao Shen1, Shripad Bhagwat1, Mark S. Sands2,3 & Brett E. Crawford1*
Krabbe disease (KD) and metachromatic leukodystrophy (MLD) are caused by accumulation of the
glycolipids galactosylceramide (GalCer) and sulfatide and their toxic metabolites psychosine and
lysosulfatide, respectively. We discovered a potent and selective small molecule inhibitor (S202) of
ceramide galactosyltransferase (CGT), the key enzyme for GalCer biosynthesis, and characterized its
use as substrate reduction therapy (SRT). Treating a KD mouse model with S202 dose-dependently
reduced GalCer and psychosine in the central (CNS) and peripheral (PNS) nervous systems and
significantly increased lifespan. Similarly, treating an MLD mouse model decreased sulfatides and
lysosulfatide levels. Interestingly, lower doses of S202 partially inhibited CGT and selectively reduced
synthesis of non-hydroxylated forms of GalCer and sulfatide, which appear to be the primary source
of psychosine and lysosulfatide. Higher doses of S202 more completely inhibited CGT and reduced
the levels of both non-hydroxylated and hydroxylated forms of GalCer and sulfatide. Despite the
significant benefits observed in murine models of KD and MLD, chronic CGT inhibition negatively
impacted both the CNS and PNS of wild-type mice. Therefore, further studies are necessary to
elucidate the full therapeutic potential of CGT inhibition.
Krabbe disease (KD) and metachromatic leukodystrophy (MLD) are severe, dysmyelinating or demyelinating
diseases of the peripheral and central nervous systems (PNS and CNS)1,2. The infantile forms are characterized
by developmental delay, loss of milestones, motor dysfunction, and death by 2–4 years of age. Krabbe disease
and MLD are caused by deficiencies in the lysosomal enzymes galactosylceramidase (GALC) and arylsulfatase
A (ARSA), respectively. Together, these enzymes catalyze the degradation of major glycosphingolipids of the
myelin sheath—galactosylceramide and sulfatide (3-O sulfated galactosylceramide) (Fig. 1). In addition, these
enzymes degrade the highly toxic, deacylated byproducts of GalCer and sulfatide metabolism, namely galactosylsphingosine (psychosine) and 3-O sulfogalactosylsphingosine (lysosulfatide), respectively. In the absence of
GALC or ARSA these toxic metabolites accumulate leading to profound demyelination. In the case of KD, it has
been shown that the accumulation of psychosine is responsible for most of the acute pathology and clinical signs3.
UDP-galactose:ceramide galactosyltransferase (CGT, EC 2.4.1.45), encoded by the UGT8 gene, catalyzes the addition of galactose from UDP-galactose to ceramide to generate GalCer (Fig. 1A). Ceramide
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Figure 1.  Synthesis and catabolism of galactosylceramide and sulfatide. CGT catalyzes the synthesis of GalCer
by adding a galactose molecule to ceramide (A). Ceramide with a hydroxy group at the 2 position (dashed
circle) is a more efficient CGT substrate than non-hydroxyceramide. CST catalyzes the sulfation of GalCer to
generate both non-hydroxy and 2-hydroxy-sulfatide (B). GalCer and sulfatide are degraded in the lysosome
by the enzymes GALC and ARSA, which are deficient in KD and MLD, respectively (C,D). GALC and ARSA
deficiency results in lysosomal accumulation of these glycolipids and their subsequent deacylation into the toxic
byproducts psychosine and lysosulfatide by acid ceramidase (E). Previous substrate reduction approaches using
L-cycloserine targets a reaction upstream from ceramide synthesis (F).
galactosyltransferase can utilize either 2-hydroxylated or non-hydroxylated ceramides as a substrate; however,
2-hydroxylated ceramides have been shown to be more efficiently galactosylated compared to non-hydroxylated
forms4,5. While CGT can generate low levels of GalCer in a variety of cell types, the enzyme is most highly
expressed in oligodendrocytes and Schwann cells during periods of active m
 yelination6. GalCers and sulfatides
make up > 25% of the lipids in mature myelin membranes with GalCer being more abundant than sulfatides6.
During myelin formation, the 2-hydroxylated and non-hydroxylated forms of these molecules are synthesized
in near equal proportions. Genetic studies using CGT knockout mice revealed GalCer synthesis is required
to produce stable myelin in the CNS and PNS and absence of CGT results in early demyelinating disease,
neurological dysfunction, and death7–9. It has been further suggested that the hydroxylated versions of these
molecules (2-hydroxy-GalCer and 2-hydroxy-sulfatide) play specific roles in stabilizing tightly packed myelin
membranes10–12. Consistent with this hypothesis, rodents and humans deficient in the fatty acid 2-hydroxylase
develop leukodystrophy13,14.
The discovery of small molecules that inhibit the synthesis of galactosylceramide-based glycolipids that accumulate in KD and MLD is an area of active r esearch15. Studies using small molecule glucosylceramide synthase
inhibitors to reduce the abundance of the glycolipids that accumulate in Gaucher disease, Fabry disease, GM1
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gangliosidosis, and GM2 gangliosidosis, have demonstrated the benefits of substrate reduction therapy16–20. Data
from mice that are completely deficient in both CGT and GALC suggest that lowering GalCer levels by CGT
inhibition provides some benefit for KD21,22. Partial loss of CGT activity in mice heterozygous for a Ugt8 null
allele show that reducing GalCer levels to approximately 70% of normal is tolerated and provides survival benefit
to Krabbe m
 ice22. However, the absence of potent and selective inhibitors of GalCer and sulfatide synthesis has
impeded the development of a substrate reduction therapy (SRT) for KD or MLD. Although L-cycloserine has
been used to evaluate the benefits of reducing the synthesis of galactosylceramide in GALC-deficient mice it
acts several steps upstream of GalCer synthesis through inhibition of serine palmitoyltransferase and is unlikely
to be used clinically due to lack of specificity and resulting toxicity (Fig. 1F)23. However, these studies provided
proof-of-concept that partially reducing psychosine levels can extend survival and reduce pathology of Krabbe
mice24–26. Although the therapeutic effect of L-cycloserine was modest, this approach synergized with orthogonal
therapeutic strategies, including bone marrow transplant and gene therapy to greatly increase e fficacy27.
We have discovered a novel, potent, selective, and brain-penetrant small molecule inhibitor of CGT (S202)
and determined its potential as an SRT to treat KD and MLD. When administered to mice, S202 significantly
decreased psychosine accumulation and increased life span of GALC-deficient Twitcher mice without overt
toxicity. Similar doses of S202 reduced lysosulfatide levels in ARSA-deficient MLD mice. However, a closer
examination of wild-type mice treated with S202 revealed negative impacts of CGT inhibition on myelin rich
tissues including brain, spine, and peripheral nerves. In total, S202 or its analogs provide a critical step forward
toward the development of a safe and efficacious SRT for KD and MLD.

Results

Discovery of a potent and selective small molecule inhibitor of CGT. A novel CGT inhibitor was
identified by screening a small, focused library of bioactive lipids for inhibitors of CGT catalytic activity. Human
CGT was obtained from lysates of CHO cells expressing human UGT8, the gene encoding CGT. A single compound was identified from this screen that weakly inhibited CGT activity (Fig. 2A). This molecule had previously been described as a cannabinoid receptor (CB1) inverse a gonist28. Surprisingly, after re-synthesizing this
screening hit based on the described structure, the CGT inhibitory activity was lost. Subsequent LC–MS analysis
of both the original and resynthesized material confirmed that these two molecules were different. After careful
evaluation of the analytical data, it was determined that the active molecule contained an additional hydroxyl
group on its central 5-member ring (Fig. 2A red text) and was likely an oxidation product of the original compound. When the hydroxylated version was synthesized (S221), CGT inhibition was restored with an IC50 of
23 µM.
Following identification of the initial low potency CGT inhibitor S221, a series of structural analogs with
increased potency were synthesized29. One analog, hereafter referred to as S202, displayed improved potency
with an I C50 of 15 nM in the cell-lysate assay and 3.6 nM (n = 6) in an intact-cell assay (Fig. 2B–D). Pharmacokinetic studies revealed that S202 had an in vivo half-life of 12.2 h and readily distributed into the mouse brain,
achieving a brain to plasma ratio of ~ 1 after 8 h (Fig. 2E,F). Through the optimization of S221 for CGT inhibitory
properties, the potency as a CB1 inverse agonist was reduced tenfold. The inhibitory activity of S202 was highly
selective for CGT, with minimal to no activity toward other enzymes that act on related glycosphingolipids (see
Supplementary Table S1 online).
CGT inhibition preferentially reduces non‑hydroxy‑GalCer synthesis in vivo. Ceramide galatosyltransferase mRNA expression peaks in mice during periods of major myelin synthesis, corresponding roughly
to postnatal days (PND) 10–30 for the CNS and PND 6–15 for the P
 NS6,30. Large quantities of galactosylceramides and sulfatides are incorporated into mature myelin with half-lives approaching 1 year31. Therefore, to evaluate the effects of CGT inhibition, wild-type mice received daily intraperitoneal (IP) injections of S202 starting
on PND3, before abundant synthesis of these glycolipids have occurred. Treatment continued until PND40, after
the majority of myelination is complete in both the CNS and PNS. S202 was well tolerated at lower doses; however, above 0.5 mg/kg produced phenotypes that were strikingly similar to those reported in the CGT knockout
mouse including reduced weight gain, mild hind limb gait abnormalities, and some animal deaths (Fig. 3A,B)21.
GalCer and sulfatide levels in S202-treated mice were monitored by LC–MS/MS. Lower doses (0.015 to
0.5 mg/kg) of S202 greatly decreased non-hydroxy-GalCer levels in the brains of wild-type mice without reducing
2-hydroxy-GalCer (Fig. 3C,D). Remarkably, lower doses of S202 were found to consistently increase 2-hydroxyGalCer levels. However, higher doses of S202 (> 1.5 mg/kg), reduced synthesis of both non-hydroxy-GalCer
and 2-hydroxy-GalCer. Like their respective GalCer precursors, treatment with lower doses of S202 selectively
reduced non-hydroxy-sulfatide and correspondingly increased 2-hydroxy-sulfatide, while higher doses reduced
total sulfatide levels (Fig. 3E,F). While these data represent the sum response of all acyl chain lengths, a similar
response was seen when individual acyl chains were monitored (see Supplementary Fig. S1 online). Preferential
reduction in non-hydroxy-GalCer and non-hydroxy-sulfatides relative to the hydroxylated versions were also
seen in the sciatic nerve. However, the effect at a given dose appeared greater in the sciatic nerve relative to the
brain. For example, a dose of 0.5 mg/kg increased 2-hydroxy GalCer and 2-hydroxy sulfatide in the brain while
partially reducing these molecules in the sciatic nerve (Fig. 3G–J).
CGT inhibition extends survival and improves pathology in a KD mouse model. To evaluate the

therapeutic potential of CGT inhibition in a relevant disease model, we treated Twitcher mice with S202. Mice
received IP injections of S202 three times per week starting on PND3 and disease progression was monitored
by the onset of clinical signs and survival. The median lifespan of untreated or vehicle treated Twitcher mice
is ~ 40 days32,33. Lower doses of S202 increased median survival to 60 days at an optimal dose of 0.15 mg/kg IP
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Figure 2.  Identification of a novel potent and brain penetrant CGT inhibitor. S221 was identified in a screen
of a focused bioactive lipid library (A). S221 was determined to be an oxidation product of (CAY10508),
which had acquired a hydroxyl group (in red) on the central ring. Through a medicinal chemistry effort S202
was discovered as a more potent CGT inhibitor (B) showing a 400-fold increased potency in a CGT enzyme
assay (C) and single digit nanomolar potency in a CGT cellular assay (D) (n = 2 per concentration). Mouse
pharmacokinetic (PK) and brain concentration profile graph (n = 3, E) and PK parameter table (F) for S202 after
a single IP injection show favorable in vivo half-life and brain penetration properties.
three times per week (Fig. 4A,B). However, higher doses of S202 were less effective and the highest dose tested
(1.5 mg/kg) reduced lifespan.
A separate cohort of Twitcher mice was dosed and sacrificed at PND28 to evaluate the biochemical and
histological effects of CGT inhibition. As observed in wild-type animals, S202 produced a dose-dependent
reduction in non-hydroxy-GalCer without reducing 2-hydroxy-GalCer in the brain (Fig. 4C,D). Surprisingly,
psychosine levels were reduced to the same extent as the non-hydroxy-GalCer, even though 2-hydroxy-GalCer
was not reduced (Fig. 4E).
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Figure 3.  Tolerability and biochemical changes in young mice treated with S202. Weight profiles of neonatal
mice (n = 4–19) treated with daily IP S202 (mg/kg/day) from PND3 to PND40 (A) and occurrence of animal
deaths and development of abnormal gait (B). LC–MS quantification of brain non-hydroxy-GalCer (C),
2-hydroxy-GalCer (D), non-hydroxy-sulfatide (E), and 2-hydroxy-sulfatide (F) from mice treated with S202.
Sciatic nerve non-hydroxy-GalCer (G), 2-hydroxy-GalCer (H), non-hydroxy-sulfatide (I), and 2-hydroxysulfatide (J) from mice treated with S202. Refer to the Materials and Methods section for significance levels.
To investigate the mechanism for this correlation between psychosine and non-hydroxy-GalCer but not
2-hydroxy-GalCer, we examined the ability of recombinant acid ceramidase to deacylate non-hydroxy-GalCer
and 2-hydroxy-GalCer in vitro. We recently showed that psychosine is produced through deacylation of GalCer
by acid ceramidase, rather than addition of galactose to sphingosine3. However, it was not clear if acid ceramidase preferred either form of GalCer. Consistent with our in vivo data, acid ceramidase was found to deacylate
non-hydroxy-GalCer much more efficiently than 2-hydroxy-GalCer (Fig. 4F). This important finding extends
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Figure 4.  CGT inhibition extends survival and reduces psychosine levels in a KD mouse model. Survival
curves of Twitcher mice treated with S202 injected IP three times per week starting on PDN3 (A) and median
days of survival (B). Untreated wild-type (UT WT) mice survived while vehicle treated Twitcher mice (vehicle)
had a median survival of 43 days. S202-treated Twitcher mice survived longer except at the highest dose tested
(1.5 mg/kg). Effect of S202 treatment on non-hydroxy-GalCer (C) and 2-hydroxy-GalCer in brain homogenates
from mice treated from PND3-PND28 (D). Psychosine reduction in these brains correlates with reduction
of non-hydroxy-GalCer (E) (n = 5–8, C–E). Quantification of psychosine generated by recombinant acid
ceramidase incubated with either purified 2-hydroxy-GalCer or non-hydroxy-GalCer substrates (n = 2 per
condition, F).
the mechanistic understanding of the origins of psychosine in Krabbe disease, indicating that psychosine is
generated specifically from deacylation of non-hydroxyl-GalCer but not hydroxylated Gal-Cer.
The effects of CGT inhibition on brain pathology were examined by immunofluorescent staining for inflammatory markers and myelin basic protein in PND28 Twitcher mice. Treatment with 0.15 mg/kg S202 IP three
times per week showed a trend toward reduction in the levels of CD68-positive macrophages (Fig. 5A,B) and
a marker of astrocytosis (GFAP, Fig. 5C,D) in Twitcher mouse brain sections. A significant reduction was seen
in a marker of myelin degeneration (MBP, Fig. 5E,F). Cytokine analysis was also performed on brain lysates
from the same animals treated with S202. Treatment reduced the levels of the macrophage markers MCP-1 and
GROA in brain homogenates (Fig. 5G,H). Twitcher mice had disorganized myelin with a relatively large number
of intensely staining puncta throughout the white matter tracts of the cerebellum (Fig. 5E). This led to an overall
increase in myelin staining compared to wild-type mice (Fig. 5F). The myelin in S202-treated animals remained
disorganized but had an apparent decrease in the number of intensely staining puncta.

Increased S202 tolerability in older Twitcher mice. To determine the effects of CGT inhibition at an
age that is roughly equivalent to the myelination status of a 1 to 2-year-old human, Twitcher mice were treated
with varying doses of S202 IP three times per week starting at PND1530. These mice showed a dose-dependent
increase in survival with a maximum median life span of ~ 63 days at 5.0 mg/kg (Fig. 6A,B). Although the
increase in median lifespan was comparable to that seen when treatment was initiated at PND3, an ~ 30-fold
greater dose was required. Like mice treated on PND3, the increase in median survival correlated with decreases
in non-hydroxy-GalCer and psychosine (Fig. 6C–E). Notably, the magnitude of the psychosine reduction was
less when treatment was started later in development and only the 1.5 mg/kg dose level achieved statistical significance.
S202 treatment reduces non‑hydroxy‑sulfatides and lysosulfatide in an MLD mouse
model. Lysosulfatide accumulation in MLD is analogous to psychosine accumulation in KD (Fig. 1E). The

ARSA-deficient mouse model of MLD has a very mild disease course; however, MLD mice do accumulate sulfatide and its cytotoxic metabolite, lysosulfatide34,35. Therefore, we measured the reduction of lysosulfatide following treatment with S202 IP three times per week. MLD mice treated with lower S202 doses showed a reducScientific Reports |
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Figure 5.  CGT inhibition improves histological and immunological markers in Twitcher mice. Brain sections
from Twitcher (Twi) mice treated with 0.15 mg/kg S202 by IP injection three times per week from PND3 to
PND28 were immunologically stained for CD68, GFAP and MBP (A,C,E) and quantified (B,D,F). Percent
immunoreactivity represents the area of staining within the region analyzed (cerebellar white matter, 100%).
Cytokine levels from brain homogenates harvested from the same mice were analyzed and MCP-1 and GROA
were reduced upon S202 treatment (G,H). N = 3–4 (A–H).
tion in non-hydroxy-sulfatide and lysosulfatide, while higher doses reduced 2-hydroxy-sulfatides (Fig. 7A–F).
Consistent with the psychosine findings, the reduction in lysosulfatide correlates with the reduction in nonhydroxy-sulfatide, suggesting acid ceramidase also prefers the non-hydroxylated form of sulfatide as a substrate.
The dose-dependent changes to sulfatide levels mirrored the responses of GalCer species to treatment whether
treatment started on PND3 or PND15.

Chronic treatment of wild‑type mice with S202.

Due to the essential role of GalCer and sulfatides
in myelin formation, we characterized the longer-term (8 week) tolerability to S202 treatment. Wild-type mice
were treated IP with S202 three times per week at doses lsimilar to those that extended median Twitcher survival
to ~ 60 days when treatment started on PND15 (2.3 mg/kg and 5.4 mg/kg). Generally, treatment with these
dose levels were well tolerated with no mortality, change in weight, or grossly abnormal clinical signs. Clini-
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Figure 6.  Older Twitcher mice better tolerate S202 but higher doses are required to increase survival. Survival
curves of Twitcher mice treated with S202 starting on PND15 (A) and median days of survival (B). Treating
Twitcher mice starting from PND15 with S202 dose dependently reduced non-hydroxy-GalCer (C), 2-hydroxyGalCer (D), and psychosine (E) (n = 3–4).

Figure 7.  S202 treatment produced similar effects on sulfatides in an MLD mouse model. ARSA knockout
mice were treated with S202 from PND3 to PND28 (n = 4, A–C) or PND15 to PND40 (n = 4, D–F). Effect of
S202 treatment on non-hydroxy-sulfatide (A,D) and 2-hydroxy-sulfatide in brain homogenates (B,E). Like
psychosine in Twitcher mice, lysosulfatide reduction in brain correlated with reduction of non-hydroxysulfatide (C,F).
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cal chemistry and hematology analysis revealed no significant effects on systemic health (see Supplementary
Table S2 online). These mice also lacked histopathological changes in the major peripheral organs, with the
notable exception of the testes and brain.
The testes of treated mice showed histopathological changes that were identical to those described in CGT
deficient mice (see Supplementary Fig. S2 online)36. Specifically, the seminiferous tubules exhibited complete
absence of spermatozoa and elongated spermatids, large numbers of intraluminal multinucleated giant cells,
prominent germ cell exfoliation with decreased germinal epithelial layers, and the absence of residual bodies.
While seemingly well tolerated, some mice treated chronically with higher (2.3 and 5.4 mg/kg) doses of S202
developed a mild gait abnormality and impaired performance on the wire hang test (Fig. 8A). We hypothesized
that these behavioral deficits resulted from CGT inhibition affecting PNS function. Therefore, nerve conduction
velocity (NCV) was measured in the sciatic nerve of treated and untreated animals. There was a significant and
dose-dependent reduction in NCV with treatment (Fig. 8B). Light microscopic examination of sciatic nerve
did not reveal obvious structural abnormalities. However, quantitative g-ratio analysis of toluidine blue stained
sections revealed a trend towards increased large diameter axons with decreased myelin thickness (Fig. 8C).
The impact of chronic S202 treatment on the CNS was evaluated by both H&E and luxol fast blue/PAS
(myelin) staining of the brain and spinal cord, revealing widespread vacuolation (Fig. 8D,E). In the brain, gray
matter vacuolation occurred in specific subsites, but was generally most extensive in the cerebral cortex, basal
ganglia, and thalamus, with less involvement in the hippocampus, pons/medulla, and cerebellum. In all affected
spinal cord segments, grey matter vacuolation was randomly scattered throughout the central area and ventral
and dorsal horns. White matter vacuolation in brain/spinal cord was sporadically distributed in various subsites
and characterized by variable size and sharply demarcated extracellular vacuoles scattered through the neuropil.
Scoring vacuolation severity by a U.S. board certified pathologist revealed that white matter vacuolation was
greater in the brain and upper spinal regions while grey matter vacuolation was more evenly distributed in all
brain and spine regions (Fig. 8F,G).
The effects of longer-term CGT inhibition on GalCer levels were evaluated in the same wild-type mice. The
selective reduction of non-hydroxy-GalCer and relative sparing of 2-hydroxy-GalCer levels observed in the
animals receiving short-term S202 was observed in chronically treated animals (see Supplementary Fig. S3
online). We hypothesized that inhibition of CGT might also alter ceramide levels, which could negatively impact
chronically treated animals. While there was only a small increase in non-hydroxy-ceramide in the animals
injected with S202 (see Supplementary Fig. S3 online), there was a dramatic increase in 2-hydroxy-ceramide in
S202-treated mice (see Supplementary Fig. S3 online).
In Twitcher mice treated with S202 starting at PND3, much lower doses (> 30 fold less) were needed to provide
the same survival benefit observed when treatment was started at PND15. Based on these findings, we speculated
that the optimal dose in younger mice was due to a balance between sufficient CGT inhibition and long-term
tolerability and that this low dose level may not produce the vacuoles observed at higher dose levels. To test this
hypothesis, wild-type mice were treated from PND3 to PND70 with 0.15 mg/kg S202 and brain, spine, and sciatic nerve were examined for signs of vacuolation. Surprisingly, even at this low dose, vacuolation was observed
in a similar pattern, but was much less severe to that seen at higher doses (see Supplementary Fig. S4 online).

Discussion

This study describes the identification and characterization of S202, a potent and selective inhibitor of CGT with
favorable drug-like properties. While having single digit nanomolar potency toward CGT, this inhibitor only
weakly inhibited the CB1 receptor ( IC50 = 3 µM), the target of its parent analog. The favorable pharmacokinetic
properties of S202 provided an opportunity to explore the consequences of CGT inhibition on myelin development and as an SRT to treat KD and MLD. These studies expand our understanding of the different roles
2-hydroxy-GalCer and non-hydroxy-GalCer play in normal development and disease progression. Finally, we
also investigate the consequences of over-inhibiting CGT at different developmental stages.
Treating wild-type mice with lower doses of S202 selectively reduced non-hydroxy-GalCer synthesis with a
corresponding increase in 2-hydroxy-GalCer. While the nature of this selective reduction is unknown, 2-hydroxyCer is a significantly more efficient substrate for CGT than non-hydroxy-Cer, possibility explaining the dosedependent reduction of one product over the other37. The selective reduction of non-hydroxy-GalCer levels,
while maintaining or even increasing 2-hydroxy-GalCer levels, could benefit the use of CGT inhibitors as an SRT
given that 2-hydroxy forms of GalCer and sulfatide are thought to be more critical for building and sustaining
the tightly packed lipid membranes of myelin s heathes6,12.
The ability to selectively reduce non-hydroxy-GalCer could have important therapeutic implications for KD.
The reduction in non-hydroxy-GalCer correlated with the reduction in psychosine in the Twitcher mice, even
while 2-hydroxy-GalCer levels were unchanged or even elevated. We also found that recombinant acid ceramidase more efficiently catabolizes non-hydroxy-GalCer to produce psychosine compared to 2-hydroxy-GalCer.
Collectively, these data suggest non-hydroxy-GalCer is the primary source of psychosine and are consistent with
the proportional reduction of non-hydroxy-GalCer and psychosine following CGT inhibition in vivo.
Treating neonatal Twitcher mice with S202 significantly increased survival. However, PND3 is an age in
mice that precedes both CNS and PNS m
 yelination30, potentially making them more sensitive to higher levels
of CGT inhibition. In addition, based on developmental milestones, a PND3 mouse corresponds roughly to a
third trimester human fetus30. Therefore, we hypothesized treatment later in development (PND15 mouse ≈
1–2 year-old human) might be better tolerated and represent a more clinically relevant time to start treatment.
When dosing was started on PND15, the tolerability to CGT inhibition greatly increased, although ~ 30-fold
higher dose levels were required to achieve similar survival as when treatment started on PND3. In PND15 mice,
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Figure 8.  Chronic CGT inhibition affects PNS and CNS function and integrity. Wild-type mice were treated
with S202 by IP injection three times per week for 8 weeks starting on PND15. The ability of mice to hang from
a wire mesh was evaluated weekly starting on week 2 of treatment (A). Sciatic NCVs were recorded from mice
that had been treated with S202 (B). G-ratio analysis of sciatic nerve (C). H&E stained brain sections from
S202 revealed vacuolation in S202 treated animals at either dose (E arrow) that was not seen in vehicle treated
animals (D). Severity of vacuolation was scored by a trained pathologist on a scale of 1–4 in white matter (F) or
gray matter (G) in brain and spinal cord. (n = 6–12).
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a significant proportion of PNS myelination is complete while CNS myelination is beginning, suggesting the
lower tolerability in younger mice could be from excessive CGT inhibition in the PNS.
When treatment was started on PND15, the percentage of non-hydroxy-GalCer and psychosine reduction
in brain was lower compared to PND3 treatment start. Similar effects were seen for non-hydroxylated sulfatide
and lysosulfatide (Fig. 7). This diminished response is likely due to preexisting non-hydroxy-GalCer, nonhydroxylated sulfatide, and/or their deacylated metabolites (psychosine and lysosulfatide) prior to treatment
start on PND15. In addition, the higher doses used in PND15 mice resulted in reduction of total GalCer levels,
including non-hydroxy-GalCer, psychosine, and 2-hydroxy-GalCer. These results suggest that reduction of total
GalCer, not just non-hydroxy-GalCer and psychosine, contribute to survival benefit when treatment starts later
in development.
Substrate reduction therapy targeting major lipid components of myelin membranes presents several challenges. These glycolipids are essential for healthy myelin formation and chronic inhibition of their synthesis
could potentially destabilize myelin. Furthermore, once synthesized and incorporated into normal myelin, these
molecules have half-lives approaching 1 year or more in humans38. With this slow turnover, SRT would need
to be initiated early in development prior to GalCer and sulfatide synthesis. Alternatively, treatment would be
required for several years before the steady state levels of GalCer and sulfatide, and ultimately psychosine and
lysosulfatide, were significantly reduced.
Although generally well-tolerated, chronic administration of higher doses of S202 to wild-type mice resulted
in dose-dependent physiological (NCV), behavioral (wire hang), and histological (vacuolation) changes. While
vacuolation occurred in both grey and white matter of the spine and brain, the severity in white matter was
greater in regions undergoing myelination during the treatment period and less in regions that had previously
undergone significant myelination. This supports the hypothesis that tissue myelinated at treatment initiation
is more resistant to adverse effects of CGT inhibition. In contrast, vacuolation observed in grey matter did not
coincide with the timing of myelination and was relatively uniform in distal spine regions and brain, possibly
indicating a novel role for CGT in non-myelinating cells such as astrocytes, microglia, neurons, or endothelial
cells. The severity, distribution, and nature of vacuolation observed in our study is similar to CGT deficient
mice as well as mice with reduced GalCer levels due to a deficiency in the Cers2 gene39–41. Further studies will be
needed to determine if this vacuolation is caused by altered levels of 2-hydroxy-ceramide, galactosylceramides,
sulfatides or currently unknown functions of CGT in non-myelinating cells.
Although treatment of Twitcher mice with S202 resulted in significantly increased life span and decreased
neuroinflammation, the improvements were modest. These results are consistent with numerous previous studies
showing monotherapies result in minor therapeutic benefit in Twitcher mice. However, studies have also found
dramatic and synergistic effects by combining disparate approaches that target different pathogenic mechanisms.
For example, while SRT using L-cycloserine alone produces an incremental increase in survival, benefits are
significantly enhanced when combined with therapies like bone marrow transplant or gene therapy. A rational
combination approach might also require lower doses of a CGT inhibitor, thereby decreasing the dose-dependent
toxicity observed with S202. Thus, the true potential of inhibiting CGT to treat patients with infantile KD might
be observed when used in combination with other therapies. Also, juvenile and adult-onset forms of KD might
respond better to CGT inhibition compared to infantile forms not only because they progress more slowly but
because they also retain residual enzyme activity that can slowly metabolize lysosomal GalCer.
Ceramide galactosyltransferase inhibition reduces non-hydroxy-sulfatide and 2-hydroxy-sulfatide and could
also be used to treat MLD. MLD is a less severe lipid storage disease potentially due to the lower abundance of
sulfatide in myelin compared to GalCer. Because MLD is slower progressing, CGT inhibition might produce
greater clinical benefits. Also, a large proportion of MLD patients are juvenile and adult-onset and could significantly benefit from lower-dose CGT inhibition. Recently, autologous stem cell gene therapy (SCGT) has resulted
in significant clinical improvements in presymptomatic MLD patients42. Adding a small molecule CGT inhibitor
to SCGT might dramatically improve the clinical outcome.
In conclusion, we have identified a novel CGT inhibitor with favorable drug-like properties that will be a
valuable tool for exploring the role that GalCer and sulfatides play in normal development and disease. This
inhibitor will be useful in exploring how galactosylceramides contribute to the biology of myelin, testes, and other
non-myelinating cells. The ability to selectively inhibit the synthesis of non-hydroxylated galactosylceramides
should be a useful attribute to enable the further understanding of the roles of the different hydroxylated species.
Given that CGT inhibitors are actively being pursued as potential SRT therapy for KD and M
 LD15, further studies
will be necessary to fully understand how to balance their safety and therapeutic benefit.

Materials and methods

Experimental design. These studies were carried out in compliance with the ARRIVE guidelines. For

these unblinded, descriptive, and novel exploratory research studies, samples sizes were chosen arbitrarily and
adjusted as needed. Most normal mouse, disease model, and tolerability studies were repeated independently,
at least twice, at different research facilities, both academic and contract research organizations, without prior
knowledge of expected outcomes. Several analogs of S202 were also tested and produced consistent findings for
survival, selective biochemical changes, and tolerability. Most endpoints were determined prospectively. No data
or outliers were excluded from the analysis unless noted in the methods. All methods were carried out in accordance with relevant guidelines and regulations.

In vitro assays. CGT enzyme assay. Human CGT was obtained from a cell lysate from CHO cells expressing UGT8 (made by BioMarin) prepared in M-PER with proteinase inhibitors (Sigma). Compounds, serially
diluted in DMSO and Tween 80, were added to 4 µg/well of CHO/CGT cell lysate to make 20 µL final reaction
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volume containing 0.5% DMSO and 0.01% Tween 80 in the reaction buffer consisting of 10 µM NDB-(2R-OH)C6 ceramide (made by BioMarin), 17.5 µM UDP-Galactose (Sigma), 35 µM of dioleoylphosphatidylcholine
(DOPC), 5 mM MgCl2, 5 mM MnCl2, 1% BSA, 15 mM KCl, 1 mM EGTA, 8 mM CHAPS, 10 mM HEPES–
NaOH pH 7.2. The reaction was incubated at 37 °C for 1 h and stopped by adding 80 µL of methanol:acetonitrile
(1:3) with 5 µM N-dodecanoyl-NBD-galactosylceramide (Matreya) internal standard (IS) for 30 min. 200 µL
H2O:ACN (1:1) was added for 5 min and then centrifuged at 4000 rpm for 38 min at RT before quantifying
NDB-(2R-OH)-C6-galactosylceramide (BioMarin) by LC–MS on a Rapid Fire 360 mass spectrometer (Agilent)
coupled with a API4000 + MS in electrospray ionization (ESI) negative mode (Applied Biosystems). These assay
conditions were used to screen the Bio-active lipid library (Cayman Cat# 10506).
Glucosylceramide synthase assay (GCS, EC 2.4.1.80). Modified from Larsen et al.46. Briefly, 60 µg of MDCK
cell lysate was incubated with S202 in 100 mM Tris buffer (pH 7.5), 10 mM M
 gCl2, 1 mM dithiothreitol, 1 mM
EGTA, 2 mM NAD, 100 μΜ UDP-glucose, 10 μΜ C6-NBD-Ceramide (Matreya), 35 μΜ DOPC, and 5 μΜ sulfatide (Sigma) at 37 °C for 1 h. The reaction was stopped with equal volume of acetonitrile and 50 μL was added
to 100 µL of acetonitrile containing 100 ng/mL tolbutamide IS and centrifuged. Next, 70 µL of supernatant was
mixed with 140 μL H
 2O before LC–MS analysis. NBD-Glucosylceramide quantification was performed on a
Shimadzu ultra-fast liquid chromatography system (Shimadzu) coupled with an API 4000 triple quadrupole
mass spectrometer in ESI positive mode (Applied Biosystems) and a Xbridge BEH130 CI 8, 100 mm × 4.6 mm
i.d, 3.5 µm column (Waters). The mobile phase consisted of water and acetonitrile supplemented with 0.1%
formic acid (v/v).
Cerebroside sulfotransferase (CST, EC 2.8.2.11). A 50 µL reaction consisting of 4 µg MPER lysate prepared from
CHO cells stably expressing GAL3ST1 cDNA construct (made by BioMarin), 3 µM N-dodecanoyl-NBD-galactosylceramide or 10 µM PAPS (Sigma) added as substrate (in DMSO/Tween 80), reaction buffer (100 mM Tris/
HCl (pH 7.0), 2.5 mM ATP, 20 mM MgCl2), and test compound. The reaction was incubated at 37 ℃ for 2 h then
stopped with 100 µL of 3:1 methanol:acetonitrile (containing 500 nM NBD-C6-OH ceramide as an IS). After 1 h
shaking, 150 µL 1:2 H2O:ACN was added, mixed, and centrifuged 4000 rpm for 30 min at RT. Supernatant was
transferred for LC–MS analysis using the same conditions used for the CGT cellular assay.
Sphingomyelin synthase (SMS, EC 2.7.8.27). 100 µL assay buffer (50 mM Tris buffer pH 7.5 containing 25 mM
KCl, 0.5 mM EDTA, 10 µM NBD-C6 ceramide, 100 µM DOPC, and 0.01% Tween 80), 60 µg MDCK cell lysate,
and serial diluted compounds were incubated at 37 ℃ for 1 h. The reaction was terminated and prepared for LC–
MS using the same protocol as the GCS assay, however, a NBD-C6-sphingomyelin (Avanti) reference standard
was used to quantify the sphingomyelin synthesis.
Beta‑glucocerebrosidase (GBA1, EC 3.2.1.45) & galactosylceramidase (GALC). Recombinant human glucosylceramidase (R&D Systems) activity was monitored using the artificial fluorescent substrate 4-methylumbelliferylβ-d-glucopyranoside (Sigma) using the assay condition on the enzyme product datasheet. Recombinant
human galactosylceramidase (R&D Systems) activity was monitored using the artificial fluorescent substrate
4-methylumbelliferyl-β-d-galactopyranoside (Sigma) using the assay conditions described on the enzyme product datasheet.
Glucosylceramidase beta 2 (GBA2, EC 3.2.1.45) assay. A postnuclear supernatant (PNS) was prepared from
HEK293 cells transiently expressing a GBA2 cDNA construct. 5 µg of PNS was added to pH 6 McIlvaine’s Buffer
(0.2 M Na2HPO4, 0.1 M citric acid) containing 0.2 mM 4-methylumbelliferyl-β-d-glucopyranoside substrate
and serially diluted S202.
Arylsulfatase A (ARSA, EC 3.1.6.8). The ARSA assay was modified from a previously reported method47.
The reaction mixture contained 40 ng of rhARSA (R&D systems), various concentrations of inhibitor, and
6.2 µM N-octadecanoyl-d3-sulfatide substrate in reaction buffer (0.08 M sodium acetate at pH 4.5, 2.08 g/L
sodium taurodeoxycholate, 33 mM M
 nCl2, 0.4% DMSO) and was incubated for 16 h at 37 °C. The reaction was
terminated with equal volume MeOH:ethyl acetate (EA). N-octadecanoyl-d35-psychosine (Matreya) was added
as the IS, together with 400 µL EA and 200 µL H2O. After centrifugation, 200 µL of the EA layer was dried under
a stream of N2 and resuspended in 100 µL MeOH before quantifying the N-octadecanoyl-d3-galactosylceramide
product using a reported UPLC–MS/MS method48.
UDP glucuronosyltransferase (UGT1A1, EC 2.4.1.17).
wan, Ltd. ITEM 196000.
CB1R activity.

UGT1A activity was evaluated at Eurofins Panlabs Tai-

CB1R activity was evaluated at Eurofin Cerep, Le Bois l’Evêque, France ITEM G012.

Blood chemistry and hematology. Maximum obtainable terminal blood collection was taken via cardiac puncture and split. 200 µL into clot-activating tubes for serum processing and the following chemistry panel: AST,
ALT, CKMB and electrolytes. 220 µL stored on wet ice and used for CBC.

CGT cellular assay.

3 × 104 CHO cells stably expressing human UGT8 were seeded in a 96-well TC plate in
F12K + 10% FBS (Invitrogen, qualified, Australia, 10099141) and incubated at 37 °C, 5% CO2 overnight. Media
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was removed and compounds, diluted in F12K + 5% FBS (0.1% DMSO final) containing 1 µM eliglustat to prevent NBD-glucosylceramide formation, were added to the cells and incubated 2 h at 37 °C. NDB-(2R-OH)C6-ceramide (BioMarin) in F12K + 5% FBS + 11% BSA was added to a final substrate concentration of 10 µM in
1% BSA and incubated 1 h at 37 °C before extracting in methanol/0.5% acetic acid containing N-dodecanoylNBD-galactosylceramide IS (1 µM). After 2 h shaking, the solution was centrifuged at 4000 rpm for 30 min, and
80 µL of supernatant was transferred to 40 µL H2O, mixed and centrifuged at 4000 rpm for 10 min. NDB-(2ROH)-C6-galactosylceramide product was quantified by a Shimadzu ultra-fast liquid chromatography system
(Shimadzu) coupled to an API 4000 mass spectrometer in ESI negative mode (Applied Biosystems) using a
Kinetex C18 column (50 × 2.1 mm, 2.6 µm, 100 Å) (Phenomenex) with 0.1% formic acid and acetonitrile supplemented with 0.1% formic acid.
In vitro psychosine production. 25 µM of 2-hydroxy-GalCer or non-hydroxy-GalCer (Matreya) were incubated
with 7 µL of purified acid ceramidase in a reaction containing 15 µL of 0.2 M citrate phosphate buffer (pH 4.5),
2.25 µL of 2 M NaCl, 1.5 µL of 10 mg/mL BSA, and 0.3 µL 10% IGEPAL CA630. The reaction was incubated at
37 °C for 18 h without agitation and then stopped by adding 60 µL of acidified methanol. Psychosine formation
was determined by LC–MS. Briefly, samples were extracted in acetonitrile containing d5-glucosysphingosine
(Avanti) IS and analyzed using a Shimadzu HPLC/Autosampler with Halo-Hilic (150 mm, 5 µm) and an API4000 Qtrap Mass Spectrometer (ESI positive, multiple reaction monitoring [MRM] scan). Mobile phase A was
0.5% FA, 5 mM N
 H4Ac in water. Mobile phase B was ACN/MeOH/0.5% FA 5 mM NH4Ac; (95/2.5/2.5). Samples
were quantified using a psychosine (Avanti) standard curve.

Mouse studies. All procedures were carried out in accordance with approved Institutional Animal Care
and Use Committee (IACUC) protocols and the BioMarin Animal Resource Committee (ARC). Twitcher mouse
studies were conducted using a protocol approved by the Washington University School of Medicine IACUC.
PND3 wild-type mouse studies and ARSA -/- studies were conducted using a protocol that was approved by the
Shanghai ChemPartner Co. IACUC. PND15 wild-type mice tolerability studies were conducted using a protocol
approved by the Jackson labs IACUC. For all animal studies S202 was formulated in 5% dimethylacetamide
(Sigma-Aldrich), 10% Solutol HS15 (Sigma-Aldrich), 85% 10 mM citrate buffer (pH 4.5).
Pharmacokinetics. C57BL/6 mice were given a single 20 mg/kg IP injection of S202 and plasma pharmacokinetics and brain tissue levels were monitored (n = 3 per timepoint). Blood was collected in K
 2 EDTA tube to
obtain a plasma sample (2000g, 5 min at 4 °C). The brain was removed, rinsed with cold saline, dried on filter
paper, weighed, and snap frozen by placing on dry ice. Brains were homogenized in 3 volumes of PBS (pH 7.4)
by mini-bead-beater before sample extraction for bioanalysis. A UPLC-MS/MS-22 (6500) was used to quantify
S202 levels relative to a Diclofenac IS and S202 standard curve. Pharmacokinetic parameters were calculated
using WinNonlin V 8.2 statistics software (Pharsight Corporation).
PND3 wild‑type mouse repeat dose studies. Wild-type C57BL/6 mice were given daily IP injections of S202
from PND3 to PND40 and weight and clinical signs were monitored daily. Animals were euthanized by exsanguinations under deep anesthesia, the brain and sciatic nerve were removed, rinsed in cold saline, dried, and
snap frozen for lipid quantification.
Twitcher mouse studies. Mice heterozygous for the Twitcher mutation on the congenic C57BL/6 background
were originally purchased from The Jackson Laboratories (stock #000845). Homozygous GALC −/− animals were generated from heterozygous mating. Genotypes were determined on PND1 by PCR as previously
described43,44. Animals that died prior to weaning on PND28 were excluded from the study unless otherwise
noted. Animals were euthanized when they became moribund as defined by any of the following: losing 25% of
their maximal body weight, ataxia severe enough to impair ability to eat or drink, or lack of response to tactile
stimulus. Animals used for tissue collection were euthanized by anesthetic overdose and perfused transcardially
with PBS for three min. Animals for lifespan analysis were euthanized using C
 O2 compressed gas delivered at
10–30% chamber volume displacement per min. Treatment IP with S202 began on either PND3-4 or PND15-16
and continued three times/week for the life of the animal. The thrice weekly dosing schedule was selected based
on the long in vivo half-life of S202 and to simplify the dosing schedule. Tissues were harvested and flash frozen
in liquid nitrogen.
ARSA knockout mice (PND3 and PND15). ARSA mice were obtained from Volkmar Gieselmann, University of
Bonn. ARSA −/− mice were generated from heterozygous pairing and confirmed by PCR genotyping. Treatment
IP with S202 began on either PND3 or PND15 and continued until PND28 or PND40 respectively. Animals were
euthanized by exsanguination under deep anesthesia and brain and sciatic nerve removed, rinsed in cold saline,
dried, and snap frozen for lipid quantification.
PND15 wild‑type mice tolerability studies. Treatment IP with S202 began on PND15-16 and continued three
times/week until PND71. Animals were euthanized with C
 O2 followed by cardiac puncture. Blood was collected
via cardiac puncture and split for blood chemistry and hematology.
Wire hang assay. Beginning on the 2nd week of treatment mice were trained weekly for two weeks. Mice are
placed on a wire grid, which is shaken to increase wire grabbing, and then immediately turned over. Mice are
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timed for their ability to hang from the inverted grid for 1 min. Three trials are performed, up to 1 min each,
with a 30 s recovery period between trials. After training, mice were tested weekly and times recorded. The test
was done with the grid held 10–12 in. over a box of clean shavings.

Young wild‑type and MLD mouse galactosylceramide and sulfatide analysis. Non‑hydroxy‑Gal‑

Cer and 2‑hydroxy‑GalCer. Whole brain was homogenized in 3 volumes H
 2O (v/w) and further diluted as
necessary in H2O. Given the small size, the sciatic nerve weight was recorded and homogenized in a larger fixed
volume. 25 µL of diluted homogenate was added to 35 µL DMSO, 200 µL of methanol, and 325 µL acetone/
methanol (50/50) and vortexed approximately 30 min. Next, 150 µL water and 300 µL water/methanol (13/87)
were added before centrifuging for 5 min at RT at 14,000 rpm. 1200 µL supernatant was transferred onto a
pre-conditioned C18-SPE cartridge, washed with 2 mL methanol/acetone/water (67/23/10), and eluted with
1.5 mL acetone/methanol (90/10). The eluate was dried before reconstituting with 50 µL DMSO (including NC16:0-CD3-Glucosylceramide, IS Matreya) and 200 ACN. 3 µL of suspension was injected into LC–MS/MS for
analysis. GalCers were separated from isobaric GluCers by Halo-Hilic (4.6 × 150 mm, 2.7 µm) column with a
mobile phase of 95/2.5/2.5 ACN/MeOH/H2O (with 0.5 FA + 5 mM N
 H4OAc) 100% for 9.5 min at 50 °C and a
0.50 mL/min flow rate. Non-hydroxy-GalCer and 2-hydroxy-GalCer were detected using MRM on an LC–MS/
MS (Agilent 6410) in positive ESI mode. Purified non-hydroxy-GalCer (Kerasin, Matreya) or 2-hydroxy-GalCer
(Phrenosin, Matreya) were used as reference standards. All non-hydroxy-GalCer or 2-hydroxy-GalCer species
identified in the reference standards were summed, normalized to the IS, and reported as percentage of vehicle
control (Fig. 2B,C). In Supplementary Figure S1, individual acyl chains were identified, normalized to the IS, and
plotted as percentage of vehicle control.
Non‑hydroxy‑sulfatide and 2‑hydroxy‑sulfatide. Previously diluted brain homogenate was serially diluted (10
µL into 90 µL and then 20 µL into 80 µL) in ACN/H2O (v/v 1:1) before being added to 300 µL ACN with IS
(N-C18:0-CD3-sulfatide, Matreya). The mixture was vortexed for 10 min, centrifuged at 5800 rpm for 10 min,
and then 3 µL of supernatant was injected for LC–MS/MS analysis. Sulfatides were separated on an ACE 5 C18
(2.1 × 50 mm, 5 µm) column (0.6 mL/min flow rate) at 60 °C using mobile phase A (H2O-5 mM NH4OAc) and
mobile phase B (ACN). Non-hydroxy-sulfatide and 2-hydroxy-sulfatide were detected using MRM on a UPLCMS/MS-22 (Triple Quad 6500) in positive ESI mode. Total sulfatides (Matreya) were used as reference standards. The non-hydroxy-sulfatide or 2-hydroxy-sulfatide species identified in the reference standards were each
summed and normalized relative to the vehicle treated animals.
Twitcher psychosine and galactosylceramide analysis. Galactosylsphingosine (psychosine), and galactosylceramide were measured by tandem mass spectrometry as previously described45. Briefly, tissue samples were
homogenized in 0.04 M citric acid. Internal controls in 200 µL methanol were added to 50 µL of each sample.
Galactosylsphingosine and galactosylceramide were separated from glucosylsphingosine and glucosylceramide
by HILIC columns. Galactosylsphingosine and galactosylceramide were detected using MRM on an AB SCIEX
4000QTRAP tandem mass spectrometer using ESI in the positive ion mode. Data were processed with Analyst
1.5.2 (Applied Biosystems). Data are reported as the peak area ratios of lipids to their ISs.
ARSA knockout lysosulfatide and sulfatide analysis. Sulfatides were quantified using the methods described
above. For lysosulfatide, 30 µL of brain homogenates were added to 200 µL ACN with IS (N-acetylsulfatide,
Matreya), vortexed for 10 min, and centrifuged at 5800 rpm for 10 min. 3 µL of supernatant was injected for LC–
MS/MS analysis. UPLC–MS/MS methods were the same used for sulfatides described above except lysosulfatide
(Matreya) was used as a reference standard.
P15 wild‑type mouse brain and sciatic nerve galactosylceramide analysis. The right midsagittal brain hemisphere was harvested, wet weights recorded, and then homogenized in 1 mL and sciatic nerve in 300 µL of H
 2O
using a Bead Ruptor Bead Mill Homogenizer (Omni International). Proteins were quantified using the BCA
Assay kit (Thermo Fisher Scientific) as described in the provided protocol and analyzed using a Tecan Infinite
M1000 plate reader. Brain homogenate was diluted to 4 µg protein/µL and sciatic nerve was diluted to 0.25 µg
protein/µL in water. 50 µL of homogenate was mixed with 500 µL of acidified methanol (95% methanol, 5% glacial acetic acid v/v) and incubated at room temperature for 2 h with intermittent vortexing (every 15–20 min).
Extracted samples were spun for 5 min at 5000 rpm, then supernatants transferred to 10 kDa centrifugal filters,
and centrifuged at 12,000 rpm for 30 min at room temperature. Ceramides and galactosylceramides were analyzed by LC–MS/MS (Waters UPLC Xevo TQ-S) using a Waters Acquity UPLC BEH C8 Column (130 Å, 1.7 µm,
1.0 mm × 150 mm) with mobile phase A (74% methanol, 25% H2O, 1% formic acid, 5 mM ammonium formate)
and mobile phase B (99% methanol, 1% formic acid, 5 mM ammonium formate). With a column temperature
of 50 °C and a flow rate of 0.07 mL/min, the initial 20% B was ramped up to 100% B in 12.0 min, maintained
until 18.0 min, returned to 20% B at 18.1 min, and sustained until 20.0 min. Quantification was done based on a
standard curve using GalCer(24:1), Cer(24:1) and Cer(24:1)2R-OH (Avanti). Hydroxy-galactosylceramide was
quantified using the non-hydroxylated standard as a proxy. Quantified ceramides are expressed as pmol per
microgram of total protein.
Twitcher mouse immunostaining. Five sections from a one in four series of sagittal brain sections from each
mouse were stained on slides using a modified immunofluorescence protocol for the following antibodies—astrocytes (rabbit anti-GFAP, 1:1000, DAKO Z0334), microglia (rat anti-mouse CD68, 1:400, Bio-Rad MCA1957),
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and myelin basic protein (MBP) (rat anti-MBP, 1:500, Merck Millipore MAB386). Briefly, 40 µm sagittal sections
were mounted on Superfrost Plus slides (Fisher Scientific), air-dried for 30 min, and blocked in 15% normal
goat serum solution (Vector Labs, S-1000) in 2% TBS-T (1 × Tris Buffered Saline, pH 7.6 with 2% Triton-X100,
Fisher Scientific) for 1 h. Slides were then incubated in primary antibody in 10% serum solution in 2% TBS-T
for 2 h. Slides were washed three times in 1×TBS and incubated in fluorescent Alexa-Fluor labelled IgG secondary antibodies (Alexa-Fluor goat anti-rabbit 488, Invitrogen A-11008 and goat anti-rat 546, Invitrogen A-11081)
in 10% serum solution in 2% TBS-T for 2 h, washed three times in 1×TBS, and incubated in a 1 × solution of
TrueBlack lipofuscin autofluorescence quencher (Biotium, Fremont, CA, #23,007) in 70% ethanol for 2 min
before rinsing in 1×TBS. Slides were coverslipped in fluoromount-G mounting medium with DAPI (Southern
Biotech). To analyze the glial activation (GFAP-positive astrocytes + CD68-positive microglia) as well as MBP
staining of punctate bodies in the cerebellar white matter, a semiautomated thresholding image analysis method
was used with Image-Pro Premier software (Media Cybernetics). Briefly, this involved the collection of slidescanned images at 5 × magnification for a one in four series of 3 sections per animal followed by demarcation
of all regions (in this case the white matter of the cerebellum) of interest while maintaining the lamp intensity,
video camera setup, and calibration constant throughout image capturing. Images were subsequently analyzed
using Image-Pro Premier using an appropriate threshold that selected the foreground immunoreactivity above
background. This threshold was then applied as a constant to all subsequent images analyzed per batch of animals and reagent used to determine the specific area of immunoreactivity for each antigen. Image densitometry
for the average pixel luminance data was also gathered for MBP staining of the cerebellar white matter due to
the higher density of staining. Slide-scanned images at 5 × magnification were collected for a one in forty-eight
series of sections per animal followed by collecting the mean luminance data across all pixels from the regions of
interest delineated using Image-Pro Premier.
Cytokine/chemokine analysis. Cytokine/chemokine analyses were performed on the brains from the same animals used for immunofluorescent imaging. Briefly, one sagittal half of the brain was homogenized in 10 mM
Tris (pH 7.5), 150 mM NaCl, 0.1% Triton X-100, and 2 mM EDTA containing a protease inhibitor cocktail
(Sigma, St. Louis, MO, cat# p8849). The lysates were adjusted to 10 mg/mL total protein with PBS, centrifuged
at 10,000 g × 10 min 4 °C to remove particulates, then 25 µL per well in duplicate was added to 25 µL PBS with
premixed magnetic beads (ThermoFisher/Procartaplex mouse simplex beads) capturing IL-10, MIP-1α, GROα, MCP-1, IP-10, IL-1β, IFNγ, IL-12p70, IL-4, IL-5, IL-6, and TNF-α. The plate was incubated overnight on a
shaker at 4 °C with the final detection steps/analysis using the Luminex FlexMAP3D performed the next morning. A calibration curve was generated from the manufacturer-expressed-protein standard using a 5-parameter
curve fitting software program (Milliplex Analyst 5.1, Verigene) and a two-fold dilution factor applied to the
extrapolated pg/mL sample values.
WT mouse tolerability study histology, morphometric analysis, and vacuole scoring. Brains were collected after
removal of the calvarium, weighted, and halved following the midline. The brain was sectioned in the midsagittal plane with half placed in 10% NBF. One sciatic nerve and other organs [heart, lung, liver, spleen, kidney,
adrenal glands, stomach, small intestine, large intestine, spinal cord (cervical, thoracic, lumbar), skin, testes, and
lymph nodes] were also collected and fixed in 10% NBF. Sections of sciatic nerve were also fixed in 2% PFA, 2%
glutaraldehyde, embedded, sectioned and stained with Toluidine blue before scanning. Images were analyzed to
determine the G-ratio in the dorsal funiculus.
NCV. Mice were anesthetized with isoflurane and placed on a thermostatically controlled heating pad to maintain body temperature. The recording electrode was inserted into the plantar muscles and a reference electrode
was placed in the skin between toes. A pair of subcutaneous stimulating electrodes were placed distally on both
sides of the ankle to stimulate the lateral plantar nerve. For proximal stimulation, the electrodes are moved to the
level of the sciatic notch, to the depth of the sciatic nerve. A current pulse was delivered at low frequency and was
gradually increased from zero until a maximal compound muscle action potential (CMAP) in the plantar muscles was evident on the oscilloscope. Six distally-produced CMAPs were recorded and stored. The procedure was
repeated using the proximal electrode pair, and current was increased until a CMAP that matches that produced
by distal stimulation was evident. Six proximally-produced CMAPs were recorded and stored. The distance
between the sites of stimulation was measured. NCV was later calculated using the two latencies and conduction
distance. The H wave was recorded during the recording of the distally stimulated CMAPs.

Statistical analysis. Significance from control group are represented as follows: * = P ≤ 0.05, ** = P ≤ 0.01,

*** = P ≤ 0.001, **** = P ≤ 0.0001. All error bars represent standard error. A two-way repeated measures ANOVA
with Tukey correction for multiple comparisons was used for weight curves and wire hang. All glycolipid bar
graphs, immunohistochemistry, and cytokine analyses used one-way ANOVA on log-transformed data with
Tukey correction for multiple comparisons. Log-rank (Mantel-Cox) test with Bonferroni correction was used
for survival curves. In vitro psychosine generation used an unpaired t-test. IC50 values were generated from
sigmoidal dose–response (variable slope) curves. Values that were below the limit of quantitation for various
bioanalytical studies were labeled BLQ and excluded from statistical analysis of log transformed data, with the
exception of MCP-1.

Data availability

S202 may be obtained through an MTA with BioMarin.
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